Gene Amplification and Overexpression at 17q in Gastric Cancer: Darpp-32
胃癌 17q 基因扩增和过度表达:Darpp-32
基本信息
- 批准号:7799138
- 负责人:
- 金额:$ 30.92万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-08-12 至 2013-04-30
- 项目状态:已结题
- 来源:
- 关键词:17q17q12-q21AKT Signaling PathwayAmino Acid SequenceApoptosisApoptoticArtsBCL-2 ProteinBiologyButyratesCamptothecinCancer EtiologyCell SurvivalCellsCeramidesCessation of lifeChromosomesClinicalClinical ManagementDARPPDNADataDatabasesDepositionDiagnosticDopamine- and cAMP-regulated neuronal phosphoproteinDrug resistanceEmbryoEquilibriumEsophageal AdenocarcinomaExpressed Sequence TagsFamilyFibroblastsFundingFutureGastric AdenocarcinomaGenbankGene AmplificationGenesHumanIn VitroIncidenceLaboratoriesLeadLengthMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMessenger RNAMitochondriaMolecularMusNamesOncogenesPI3K/AKTPTEN genePTEN proteinPathway interactionsPatientsPeptide Sequence DeterminationPharmaceutical PreparationsPopulationPreventivePropertyProtein FamilyProtein IsoformsProteinsProteomicsRNA SplicingRelative (related person)ResearchResistanceRoleSamplingSignal PathwaySignal TransductionSignaling MoleculeStomachStomach CarcinomaSurvival RateTFF1 geneTherapeuticTimeTissue MicroarrayTransgenic MiceUnited StatesUp-RegulationVariantWorkXenograft procedurebasecancer cellcarcinogenesisclinically significantcombatin vivomalignant stomach neoplasmmembermouse modelnoveloverexpressionphosphoprotein 32promoterprotein Bprotein activationpublic health relevanceresearch studytumortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Gastric carcinoma (GC) is the second most common cause of cancer-related death worldwide. Moreover, a sharp increase in incidence of proximal Gastroesophageal Junctional (GEJ) and esophageal adenocarcinomas was recently noted in the United States as well as many other Western populations. The critical molecular alterations that drive gastric tumorigenesis remain largely uncharacterized. Overall relative 5- year survival rates are currently less than 20%. Improvement in our presently limited diagnostic, preventive, and therapeutic approach to gastric cancer is currently a pressing issue. During the previous funding period, we have successfully completed all original aims and systematically characterized the chromosome 17q amplicon in gastric cancer. We have cloned and identified, for the first time, Dopamine- and cAMP-regulated neuronal phosphoprotein 32 kDa (DARPP-32) and a novel transcriptional splice variant that encodes a truncated protein isoform that we named t-DARPP as novel cancer genes with potent anti-apoptotic and drug resistance properties. DARPP-32 and t-DARPP mRNAs and proteins are overexpressed in more than two- thirds of GCs, thus becoming prevalent molecular changes in these tumors. In this proposal, we plan to continue our work and characterize the in vitro and in vivo role(s) of DARPP-32 and t-DARPP proteins in modulation of gastric tumorigenesis and pro-survival pathways. We hypothesize, based on our preliminary data, that over-expression of DARPP-32 proteins is an important molecular mechanism during gastric tumorigenesis. In this proposal, we will investigate the clinical, molecular, and pathobiological roles of DARPP-32 and t-DARPP in GCs. In this proposal, we will analyze, on tissue microarrays that contain more than 300 tumor samples, the expression of DARPP-32 proteins with other proteins (pAkt and PTEN) that regulate cancer cell survival. We will investigate the mechanism(s) by which DARPP-32 and t-DARPP regulate the PTEN-PI3K/AKT signaling pathway. The role of DARPP-32/t-DARPP in modulation of PI3K survival pathway is a novel and a previously unexplored mechanism in GCs. We will also explore the role of DARPP-32/t-DARPP in regulating the balance between the pro-apoptotic and pro-survival members of the BCL-2 family proteins. Using advanced proteomic approaches, we plan to identify downstream signaling targets of DARPP-32 and t-DARPP proteins in cancer. This step is expected to reveal novel molecular signaling pathways that are regulated by these proteins in GC. In order to study the role of t-DARPP in gastric tumorigeneses in vivo, we will develop a transgenic mouse model using the TFF1 promoter to drive the t-DARPP expression in the glandular stomach. We expect that completion of this proposal will provide important clinical, molecular, and pathobiological information that have significant impact on the clinical management of patients with adenocarcinomas of the stomach. PUBLIC HEALTH RELEVANCE: This proposal connects in vitro and in vivo experiments in order to characterize the role(s) of Darpp-32 proteins in gastric carcinogenesis. We plan to investigate the contribution of Darpp-32 proteins to PI3K/Akt survival pathway. Using state-of-the-art proteomics approaches, we expect to reveal novel signaling molecules and pathways for these proteins in cancer.
描述(由申请人提供):胃癌(GC)是全球癌症相关死亡的第二大常见原因。此外,近端胃食管交界处(GEJ)和食管腺癌的发病率急剧增加,最近在美国以及许多其他西方国家的人口。驱动胃肿瘤发生的关键分子变化在很大程度上仍然没有得到表征。总体相对5年生存率目前低于20%。改善我们目前有限的诊断,预防和治疗胃癌的方法是目前一个紧迫的问题。在上一个资助期间,我们成功地完成了所有最初的目标,并系统地描述了胃癌中染色体17 q扩增子的特征。我们已经克隆和鉴定,第一次,多巴胺和cAMP调节的神经元磷蛋白32 kDa(DARPP-32)和一种新的转录剪接变异体,编码一种截短的蛋白质亚型,我们命名为t-DARPP作为新的癌症基因,具有有效的抗凋亡和耐药性。DARPP-32和t-DARPP mRNA和蛋白在超过三分之二的GC中过表达,因此成为这些肿瘤中普遍的分子变化。在这项提议中,我们计划继续我们的工作,并表征DARPP-32和t-DARPP蛋白在调节胃肿瘤发生和促生存途径中的体外和体内作用。我们推测,根据我们的初步数据,DARPP-32蛋白的过度表达是胃肿瘤发生过程中的一个重要分子机制。在这个提议中,我们将研究DARPP-32和t-DARPP在GC中的临床、分子和病理生物学作用。在这项提案中,我们将在包含300多个肿瘤样本的组织微阵列上分析DARPP-32蛋白与其他调节癌细胞存活的蛋白(pAkt和PTEN)的表达。我们将研究DARPP-32和t-DARPP调节PTEN-PI 3 K/AKT信号通路的机制。DARPP-32/t-DARPP在PI 3 K生存途径调节中的作用是GC中一种新颖且以前未探索的机制。我们还将探索DARPP-32/t-DARPP在调节BCL-2家族蛋白的促凋亡和促存活成员之间的平衡中的作用。利用先进的蛋白质组学方法,我们计划确定DARPP-32和t-DARPP蛋白在癌症中的下游信号靶标。这一步骤有望揭示GC中受这些蛋白质调控的新分子信号通路。为了研究t-DARPP在体内胃肿瘤发生中的作用,我们将建立一种使用TFF 1启动子驱动t-DARPP在腺胃中表达的转基因小鼠模型。我们希望完成这一建议将提供重要的临床,分子和病理生物学信息,有显着的影响,对胃腺癌患者的临床管理。公共卫生相关性:本研究将体外和体内实验相结合,以表征Darpp-32蛋白在胃癌发生中的作用。我们计划研究Darpp-32蛋白对PI 3 K/Akt存活通路的贡献。使用最先进的蛋白质组学方法,我们希望揭示癌症中这些蛋白质的新信号分子和途径。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WAEL EL-RIFAI其他文献
WAEL EL-RIFAI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WAEL EL-RIFAI', 18)}}的其他基金
Intercepting novel functions of AURKA in gastric tumorigenesis
拦截 AURKA 在胃肿瘤发生中的新功能
- 批准号:
10663953 - 财政年份:2022
- 资助金额:
$ 30.92万 - 项目类别:
Disruption of Transcription Networks in Esophageal Adenocarcinoma Tumorigenesis
食管腺癌肿瘤发生中转录网络的破坏
- 批准号:
10407744 - 财政年份:2022
- 资助金额:
$ 30.92万 - 项目类别:
Disruption of Transcription Networks in Esophageal Adenocarcinoma Tumorigenesis
食管腺癌肿瘤发生中转录网络的破坏
- 批准号:
10662298 - 财政年份:2022
- 资助金额:
$ 30.92万 - 项目类别:
Elucidating Novel APE1 Redox-Dependent Functions in Esophageal Adenocarcinoma
阐明食管腺癌中新型 APE1 氧化还原依赖性功能
- 批准号:
10662300 - 财政年份:2022
- 资助金额:
$ 30.92万 - 项目类别:
Elucidating Novel APE1 Redox-Dependent Functions in Esophageal Adenocarcinoma
阐明食管腺癌中新型 APE1 氧化还原依赖性功能
- 批准号:
10407745 - 财政年份:2022
- 资助金额:
$ 30.92万 - 项目类别:
Intercepting novel functions of AURKA in gastric tumorigenesis
拦截 AURKA 在胃肿瘤发生中的新功能
- 批准号:
10515693 - 财政年份:2022
- 资助金额:
$ 30.92万 - 项目类别:
Molecular Functions of CDK1 in Gastric Tumorigenesis
CDK1在胃肿瘤发生中的分子功能
- 批准号:
10546490 - 财政年份:2021
- 资助金额:
$ 30.92万 - 项目类别:
Molecular Functions of CDK1 in Gastric Tumorigenesis
CDK1在胃肿瘤发生中的分子功能
- 批准号:
10117581 - 财政年份:2021
- 资助金额:
$ 30.92万 - 项目类别:














{{item.name}}会员




